Philippines

Population 2017  
105 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>26 (23–31)</td>
<td>25 (22–29)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.38 (0–3.3)</td>
<td>0.36 (0–3.1)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>581 (326–909)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>7.1 (2.9–13)</td>
<td>6.7 (2.8–12)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>27 (12–47)</td>
<td>26 (12–45)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated TB incidence by age and sex (thousands)*, 2017</th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>37 (33–42)</td>
<td>371 (223–519)</td>
<td>408 (237–580)</td>
</tr>
<tr>
<td>Total</td>
<td>71 (59–84)</td>
<td>510 (271–749)</td>
<td>581 (326–909)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017
Total cases notified 328,773
Total new and relapse 317,266
- % tested with rapid diagnostics at time of diagnosis 26%
- % with known HIV status 24%
- % pulmonary 98%
- % bacteriologically confirmed among pulmonary 39%

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2017 55% (35–97)
TB patients facing catastrophic total costs, 2017 35%
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.05 (0.03–0.08)

TB/HIV care in new and relapse TB patients, 2017
Number (%) Patients with known HIV-status who are HIV-positive 1,335 2%
- on antiretroviral therapy 1,185 89%

Drug-resistant TB care, 2017
Estimated MDR/RR-TB cases among notified pulmonary TB cases 20,000 (18,000–22,000)
Estimated % of TB cases with MDR/RR-TB 2.6% (1.9–3.4) 28% (27–28)
% notified tested for rifampicin resistance 19% 83% 93,058
MDR/RR-TB cases tested for resistance to second-line drugs 2,401
Laboratory-confirmed cases
Patients started on treatment ****
MDR/RR-TB: 6,438, XDR-TB: 15
MDR/RR-TB: 5,623, XDR-TB: 16

Treatment success rate and cohort size
New and relapse cases registered in 2016 91% 332,308
Previously treated cases, excluding relapse, registered in 2016 80% 10,097
HIV-positive TB cases registered in 2016 82% 8,899
MDR/RR-TB cases started on second-line treatment in 2015 54% 3,851
XDR-TB cases started on second-line treatment in 2015 33% 9

TB preventive treatment, 2017
% of HIV-positive people (newly enrolled in care) on preventive treatment 57%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 12% (11–13)

TB financing, 2018
National TB budget (US$ millions) 160
Funding source: 37% domestic, 21% international, 42% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed.

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-01-17